EVOGENE (EVGN)

At the center of Evogene’s strategy is its Computational Predictive Biology platform. The platform is designed to analyze biological data and predict useful microbes, small molecules, and genetic elements before they move into laboratory validation and development. This approach aims to shorten discovery timelines and improve the probability of finding candidates with desirable traits, whether for therapeutics, crop protection, seed traits, or industrial uses.

Evogene operates through a group of subsidiaries and affiliated activities that apply the platform to specific markets. These include microbiome-based therapeutics for human health, agricultural biologicals, agricultural chemicals, cannabis-related product development, seed traits, and castor-based industrial agriculture. Publicly associated subsidiaries include businesses focused on areas such as microbiome therapeutics, ag-biological solutions, crop-protection chemistry, and castor seed development.

The company generates revenue across its activities, with the industrial segment contributing the largest share, followed by agriculture. Its business model can include product development, collaborations, and commercialization through subsidiaries or partners, depending on the field.

Evogene is distinctive because it is not built around a single drug, crop input, or seed variety. Instead, it acts as a biology discovery platform company, using computational tools to search across multiple life-science categories. This gives it exposure to several markets where improved prediction, biological understanding, and targeted development can create value.